Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material in the ... there are a considerable number of terms in popular use to describe it, ophthalmologists ... a mixture of mucus, blood cells, skin cells and dust, but until now there ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the company is making good progress in evaluating the full range of capabilities ... stem cells. Adult tissue stem cells perform the day-to-day renewal and repair of ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... where scientists and engineers assemble spacecraft, have joined ... unlikely places where scientists have discovered ultra-hardy organisms ... uncovered in a recent NASA study have never ... Kasthuri Venkateswaran, who led the study conducted at ...
... a method for culturing mammalian neurons in chambers not much ... lifespan of the neurons at very low densities, an essential ... behavior of individual brain cells. , The technique is described ... Chemistry Lab on a Chip. , This finding will ...
... casting, splinting and bracing technology, ST. ... Technologies,Inc. of St. Paul, Minn., and Product ... to announce the launch of Exos Corporation, ... commercialize innovative orthopedic,support devices. Exos will ...
Cached Biology Technology:NASA study will help stop stowaways to Mars 2Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3Enova Medical Launches Exos Corporation 2
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the most important resource for the world's population, and their ... discussion during the seminar 'A new look on the ocean' ... primary focus of the seminar will be on utilisation and ... and society. Friedhelm Schröder and Wilhelm Petersen of the GKSS ...
... it's a daunting task to find a smoking gun ... to say not just when and how a specific ... translated into real-world dominance of one population over another. ... forced bacteria to compete in a head-to-head contest for ...
... St. Jude Children's Research Hospital have announced that a ... antigenic variant of the avian influenza virus H5N1 may ... based on this model might therefore be suitable for ... a new vaccine could be developed specifically against the ...
Cached Biology News:A new look at the state of the oceans 2A new look at the state of the oceans 3Ready, set, mutate?and may the best microbe win 2Ready, set, mutate?and may the best microbe win 3Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Rad51B...
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Biology Products: